Catalys Pacific, LLC

In its 13F for Q3 2025 (holdings as of September 30, 2025, filed November 14, 2025), Catalys Pacific, LLC reported 2 stock positions worth $351.4 million. Its top holding was Mineralys Therapeutics (MLYS) at 96.1% of the portfolio, followed by Phathom Pharmaceuticals (PHAT, 3.9%). Its holdings were unchanged from Q2 2025.

Most Recent 13F
Q2 2026
Location
TOKYO, M0
CIK
0002011385
Portfolio Value
$351.4M (Q3 2025)
SEC Filing
0001104659-25-112029 ↗ filed Nov 14, 2025

Holdings Value

0$100.0M$200.0M$300.0M$400.0M Q1 2024: $148.1M Q1 2024 Q2 2024: $132.5M Q2 2024 Q3 2024: $125.4M Q3 2024 Q4 2024: $115.9M Q4 2024 Q1 2025: $148.7M Q1 2025 Q2 2025: $131.7M Q2 2025 Q3 2025: $351.4M $351.4M Q3 2025 Q4 2025: $310.5M Q4 2025 Q1 2026: $230.7M Q1 2026 Q2 2026: $229.5M Q2 2026

Holdings 2 stocks · $351.4M
MLYS Mineralys Therapeutics Inc. 96.09% 8,903,838 $337.6M No change
PHAT Phathom Pharmaceuticals Inc. 3.91% 1,167,114 $13.7M No change

Portfolio Sells Q2 2025 → Q3 2025
None this quarter.

Portfolio Buys Q2 2025 → Q3 2025
None this quarter.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 2$229.5MMLYS, PHAT
Q1 2026 2$230.7MMLYS, PHAT
Q4 2025 2$310.5MMLYS, PHAT
Q3 2025 2$351.4MMLYS, PHAT
Q2 2025 2$131.7MMLYS, PHAT
Q1 2025Amended 2$148.7MMLYS, PHAT
Q4 2024 2$115.9MMLYS, PHAT
Q3 2024 3$125.4MMLYS, PHAT, HLVX
Q2 2024 3$132.5MMLYS, HLVX, PHAT
Q1 2024 3$148.1MMLYS, HLVX, PHAT